These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34219057)

  • 1. [CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.].
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Arch Esp Urol; 2021 Jul; 74(6):554-563. PubMed ID: 34219057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Arch Esp Urol; 2022 Aug; 75(6):507-516. PubMed ID: 36138499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
    Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
    ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
    Hernández Hernández C; Kim Lee D; Sanchez Pérez M; Escobar SH
    Clin Genitourin Cancer; 2019 Jun; 17(3):e645-e649. PubMed ID: 31097389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    Cooperberg MR; Broering JM; Carroll PR
    J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.